Clinical and molecular characteristics of PTLs, PCNSLs and DLBCLs
| . | . | PTL . | PCNSL . | DLBCL . |
|---|---|---|---|---|
| (n = 25) . | (n = 22) . | (n = 22) . | ||
| Age, y | Median (range) | 74 (58-89) | 69 (49-83) | 63 (4-89) |
| Gender | Male | 100 (25/25) | 67 (14/21) | 64 (14/22) |
| Female | 0 (0/25) | 33 (7/21) | 36 (8/22) | |
| EBV status | Positive | 0 (0/25) | 15 (3/20) | 9 (2/22) |
| MYC | Rearranged | 8 (2/25) | 0 (0/15) | 5 (1/22) |
| BCL2 | Rearranged | 0 (0/25) | 6 (1/17) | 0 (0/22) |
| BCL6 | Rearranged | 25 (6/24) | 19 (3/16) | 32 (7/22) |
| MYD88 | Mutated | 76 (19/25) | 64 (14/22) | 32 (7/22)** |
| CD79B | Mutated | 20 (5/25) | 23 (5/22) | 14 (3/22) |
| COO | Non-GCB | 76 (19/25) | 95 (21/22) | 86 (19/22) |
| GCB | 24 (6/25) | 5 (1/22) | 14 (3/22) | |
| PD-L1 tumor | Negative | 92 (23/25) | 82 (18/22) | 73 (16/22) |
| Weak | 0 (0/25) | 4 (1/22) | 9 (2/22) | |
| Positive | 8 (2/25) | 14 (3/22) | 18 (4/22) | |
| PD-L1/2 CNA | Gain | 4 (1/23) | 0 (0/13) | 14 (3/22) |
| Polysomy | 0 (0/23) | 0 (0/13) | 0 (0/22) | |
| HLA class I | Loss | 68 (17/25) | 64 (14/22) | 32 (7/22)* |
| HLA class II | Loss | 84 (21/25) | 59 (13/22) | 14 (3/22)** |
| . | . | PTL . | PCNSL . | DLBCL . |
|---|---|---|---|---|
| (n = 25) . | (n = 22) . | (n = 22) . | ||
| Age, y | Median (range) | 74 (58-89) | 69 (49-83) | 63 (4-89) |
| Gender | Male | 100 (25/25) | 67 (14/21) | 64 (14/22) |
| Female | 0 (0/25) | 33 (7/21) | 36 (8/22) | |
| EBV status | Positive | 0 (0/25) | 15 (3/20) | 9 (2/22) |
| MYC | Rearranged | 8 (2/25) | 0 (0/15) | 5 (1/22) |
| BCL2 | Rearranged | 0 (0/25) | 6 (1/17) | 0 (0/22) |
| BCL6 | Rearranged | 25 (6/24) | 19 (3/16) | 32 (7/22) |
| MYD88 | Mutated | 76 (19/25) | 64 (14/22) | 32 (7/22)** |
| CD79B | Mutated | 20 (5/25) | 23 (5/22) | 14 (3/22) |
| COO | Non-GCB | 76 (19/25) | 95 (21/22) | 86 (19/22) |
| GCB | 24 (6/25) | 5 (1/22) | 14 (3/22) | |
| PD-L1 tumor | Negative | 92 (23/25) | 82 (18/22) | 73 (16/22) |
| Weak | 0 (0/25) | 4 (1/22) | 9 (2/22) | |
| Positive | 8 (2/25) | 14 (3/22) | 18 (4/22) | |
| PD-L1/2 CNA | Gain | 4 (1/23) | 0 (0/13) | 14 (3/22) |
| Polysomy | 0 (0/23) | 0 (0/13) | 0 (0/22) | |
| HLA class I | Loss | 68 (17/25) | 64 (14/22) | 32 (7/22)* |
| HLA class II | Loss | 84 (21/25) | 59 (13/22) | 14 (3/22)** |
Unless stated otherwise, data are expressed as percentage of cases that were positive (positive cases/total cases examined). The correlation between the clinical and molecular characteristics among the different tumor types was examined using the χ2 test. P-values were 2-sided and P < .05 was considered statistically significant. *P < .05; **P < .01.
COO, cell of origin.